Erratum (Alternate Day Micafungin Anti-Fungal Prophylaxis In Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study (2010) 16(10) (1458–1462), (S1083879110002004), (10.1016/j.bbmt.2010.05.002));Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 10, 2010, Pages 1458-1462

  Mehta, Parinda A ^a   Vinks, Alexander A ^a   Filipovich, Alexandra ^a   Bleesing, Jack ^a   Jodele, Sonata ^a   Jordan, Michael B ^a   Marsh, Rebecca ^a   Tarin, Richard ^a   Edwards, Stephanie ^a   Fearing, Deborah ^a   Lawrence, Julia ^a   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Hematopoietic stem cell transplantation; Micafungin; Pharmcokinetics; Prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; MICAFUNGIN; MICAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW DEPRESSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; EWING SARCOMA; FANCONI ANEMIA; FEMALE; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; INFANT; INFECTION PREVENTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAINTENANCE THERAPY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEUROBLASTOMA; OPEN STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN BINDING; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; WISKOTT ALDRICH SYNDROME;

EID: 77956287727     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.009     Document Type: Erratum

References (29)

1. Abbasi S., Shenep J.L., Hughes W.T., Flynn P.M. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999, 29:1210-1219.
2. Groll A.H., Muller F.M., Piscitelli S.C., Walsh T.J. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998, 210:264-273.
3. Hovi L., Saarinen-Pihkala U.M., Vettenranta K., Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000, 26:999-1004.
4. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., Hollis R.J. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002, 40:852-856.
5. Menichetti F., Del Favero A., Martino P., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999, 28:250-255.
6. Bodey G.P., Anaissie E.J., Elting L.S., Estey E., O'Brien S., Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994, 73:2099-2106.
7. Lyman C.A., Walsh T.J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992, 44:9-35.
8. Hatano K., Morishita Y., Nakai T., Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002, 55:219-222.
9. Ikeda F., Wakai Y., Matsumoto S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000, 44:614-618.
10. Matsumoto S., Wakai Y., Nakai T., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000, 44:619-621.
11. Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000, 46:485-487.
12. Petraitis V., Petraitiene R., Groll A.H., et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002, 46:1857-1869.
13. Tawara S., Ikeda F., Maki K., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000, 44:57-62.
14. Groll A.H., Mickiene D., Petraitis V., et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001, 45:3322-3327.
15. Pettengell K., Mynhardt J., Kluyts T., Lau W., Facklam D., Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004, 20:475-481.
16. Seibel N.L., Schwartz C., Arrieta A., et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005, 49:3317-3324.
17. Carter N.J., Keating G.M. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs 2009, 11:271-291.
18. Kawada M., Fukuoka N., Kondo M., et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J 2009, 28:840-842.
19. Hebert M.F., Smith H.E., Marbury T.C., et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005, 45:1145-1152.
20. Hebert M.F., Blough D.K., Townsend R.W., et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005, 45:1018-1024.
21. Wang J.L., Chang C.H., Young-Xu Y., Chan K.A. Tolerability and hepatotoxicity of antifungal use in empirical and definitive therapy for invasive fungal infection: a systematic review and meta-analysis. Antimicrob Agents Chemother 2010, Mar 22 [Epub ahead of print].
22. Gumbo T., Drusano G.L., Liu W., et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007, 51:968-974.
23. Buell D, Kovada L, Drake T, Fisco C. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. 47th Annual conference of American Society of Hematology 2005: abstr. 719.
24. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., Klepser M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002, 46:3846-3853.
25. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154.
26. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46:2620-2629.
27. Arikan S., Yurdakul P., Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003, 47:2640-2643.
28. Ikeda F., Saika T., Sato Y., et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol 2009, 47:145-148.
29. Mouton JW GE, Curfs-Breuker I, Klaassen CH, Meis JF. Susceptibility of micafungin in Candida strains isolated from patients with invasive Candida infections by EUCAST methodology. 4th Trends in Medical Mycology, Athens, Greece, 2009.